Regeneron Pharmaceuticals Investors Alerted to Lawsuit Over Delayed Clinical Trial

Regeneron Pharmaceuticals (NASDAQ: REGN) is facing a securities class action lawsuit stemming from recent disclosures concerning a Phase 3 clinical trial. Investors have been alerted to a September 14, 2026 deadline to act as lead plaintiff in the litigation.

The lawsuit alleges that the company provided misleading information to investors regarding the timeline and outcomes of the trial. It is claimed that Regeneron failed to timely and accurately disclose significant delays and potential issues affecting the study's progression.

The class action targets investors who purchased Regeneron stock during a specified period and subsequently incurred losses due to the allegedly misleading statements made by the company. Further details regarding the case and its requirements are available through legal channels.

Recent announcements regarding the delay in the company's Phase 3 drug trial have generated concern among shareholders. Potential legal ramifications and impacts on the company's reputation and stock performance are under scrutiny.